|Articles|April 13, 2016
Implications of Mid-Study Clinical Trial Protocol Changes
Advertisement
Medidata & Tufts Center for the Study of Drug Development announced results of a study on the impact of protocol amendmends made while a clinical trial is underway. The study discussed their avoidability, costs and time delays.
Read the full release
Read more in Kenneth Getz’s column this month
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results
4
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
